Treatment of Sepsis with Talactoferrin

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$2,462,040.00
Award Year:
2008
Program:
SBIR
Phase:
Phase II
Contract:
4R44GM077816-02
Agency Tracking Number:
GM077816
Solicitation Year:
2008
Solicitation Topic Code:
n/a
Solicitation Number:
PHS2007-2
Small Business Information
AGENNIX, INC.
AGENNIX, INC., 8 GREENWAY PLZ, STE 910, HOUSTON, TX, 77046
Hubzone Owned:
Y
Socially and Economically Disadvantaged:
Y
Woman Owned:
Y
Duns:
808956700
Principal Investigator:
ATUL VARADHACHARY
(713) 552-1091
AVARADHACHARY@AGENNIX.COM
Business Contact:
(713) 552-1091
msmith@agennix.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Severe sepsis is a major cause of morbidity and mortality throughout the world. It is the leading cause of death in non-coronary intensive care units (ICUs) in the United States, with more than 750,000 cases occurring every year. This means that in the United States, more than 500 patients die from severe sepsis every day, with 28% to 50% of the patients succumbing to the disease process at an average cost of $22,000 per patient. Successful development of TLF-based therapy for sepsis would satisfy a significant unmet medical need. Agennix has now established a manufacture of a pharmaceutical-grade talactoferrin, it has demonstrated its safety in clinical studies for various indications, and is now interacting with the FDA to obtain a go-ahead to initiate clinical Phase 3 studies in cancer. The development of talactoferrin is therefore at a stage that a demonstration of its clinical efficacy in sepsis would put the generation of a product to treat sepsis on a relatively easy and straightforward path.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government